Journal
FUTURE MICROBIOLOGY
Volume 8, Issue 4, Pages 491-507Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.13.16
Keywords
efflux; efflux pump inhibitor; MepA; multidrug resistance; NorA; Staphylococcus aureus
Categories
Funding
- Veterans Affairs Biomedical Laboratory Research and Development funds [1IO1BX000465]
Ask authors/readers for more resources
The emergence of multidrug-resistant Staphylococcus aureus coupled with a declining output of new antibiotic treatment options from the pharmaceutical industry is a growing worldwide healthcare problem. Multidrug efflux pumps are known to play a role in antibiotic and biocide resistance in S. aureus. These membrane transporters are capable of extruding drugs and other structurally unrelated compounds, hence decreasing intracellular concentration and increasing survival. Coadministration of efflux pump inhibitors (EPIs) with antibiotics that are pump substrates could increase intracellular drug levels, thus bringing renewed efficacy to existing antistaphylococcal agents. Numerous EPIs have been identified or synthesized over the past two decades; these include existing pharmacologic drugs, naturally occurring compounds, and synthetic derivatives thereof. This review describes the current progress in EPI development for use against S. aureus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available